Advertisement


Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors

2023 SABCS

Advertisement

Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Foundation Trust, and the Institute of Cancer Research, London, discusses the monarchE trial, which evaluated molecular profiling of archived primary tumor tissue from patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early-stage breast cancer and its potential association with clinical outcomes. Adjuvant abemaciclib plus endocrine therapy (ET) maintained invasive disease–free survival benefit compared with ET alone across all molecular subtypes as measured by RNA sequencing (Abstract GS03-06).



Related Videos

Breast Cancer

Sherene Loi, MD, PhD, on Biomarker Results in ER+, HER2– Primary Breast Cancer Following Neoadjuvant Chemotherapy With or Without Nivolumab

Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates with the addition of nivolumab to neoadjuvant chemotherapy (Abstract GS01-01).

Breast Cancer

Daniel G. Stover, MD, on Early-Stage Breast Cancer: A Biomarker Analysis From the PALLAS Trial

Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage II–III hormone receptor–positive, HER2-negative breast cancer. The genomic subtype PAM50 was defined in the protocol of the PALLAS trial as the primary biomarker for analysis of prediction and prognosis (Abstract GS03-07).

Breast Cancer

Seema Khan, MD, on Ductal Carcinoma in Situ: Central MRI and a 12-Gene Expression Assay to Optimize Local Therapy

Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score and its use in patients with intermediate/high DCIS scores (Abstract GS03-01).

Breast Cancer

Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel

Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in nivolumab. Those with immune-enriched tumors had high pathologic complete response rates, identifying a subpopulation for whom a 12-week anthracycline-free chemotherapy regimen with nivolumab may be appropriate (Abstract LBO1-03).

Breast Cancer

Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).

Advertisement

Advertisement




Advertisement